Keywords
COVID-19 - vulvar lesion - viral swab - vertical transmission - personal protective
equipment
We present a case of a pregnant woman with simultaneous upper respiratory symptoms
and vulvovaginitis. She was found to have a vulvar lesion positive for COVID-19 by
viral swab. While current research suggests that COVID-19 viral antigen is not found
in vaginal secretions,[1]
[2] other lower genital tract shedding or manifestations may have clinical implications
for obstetrician-gynecologists.
The patient, a 26-year-old G3P1011 at 31 weeks' gestation with a history of chronic
hypertension, presented to a routine prenatal visit. She reported recent history of
cough, fatigue, myalgias, anosmia, and ageusia. She denied fevers or sick contacts.
Despite these symptoms, she was most bothered by vulvovaginitis, reporting vulvar
pruritis and burning. On physical examination, she was found to have normal vital
signs, cardiopulmonary examination, fundal height, and fetal heart tones. On chaperoned
pelvic examination, a 3-mm ulceration in the right posterior fourchette of the vaginal
introitus was noted, and a viral swab was performed to be sent for herpes simplex
virus (HSV) viral polymerase chain reaction (PCR) testing. She was also diagnosed
with a candida yeast infection of the vulva and prescribed fluconazole. Given her
other reported symptoms, a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
nasopharyngeal test was also ordered, and the patient was instructed to have the test
performed at an offsite outpatient testing site specifically designated for this purpose.
Results returned 3 days later. The RT-PCR testing, specifically Roche Diagnostics'cobas
SARS-CoV-2 Test run on the cobas 8800 System, resulted as negative for SARS-CoV-2
RNA but positive for Pan-SARS RNA, a less specific but more sensitive assay within
the dual target test. The processing laboratory clarified that this should be treated
as a presumptive positive test for SARS-CoV-2. The patient was contacted, but she
reported that she had not yet gone for outpatient nasopharyngeal testing. At this
time, it was discovered that the viral swab from the vulvar lesion had been inadvertently
labeled as a nasopharyngeal swab and sent for SARS-CoV-2 testing rather than HSV testing.
The patient was contacted and immediately informed of the error. Isolation precautions
were reviewed, and she agreed to present to the clinic the next day with appropriate
infection prevention precautions in place for a nasopharyngeal swab and repeat HSV
swab of the vulvar lesion. The vulvar lesion specimen returned negative for HSV-1
and HSV-2. However, her nasopharyngeal swab, which was processed using the same Roche
cobas dual target assay and 8800 system, returned positive for SARS-CoV-2 RNA and
Pan-SARS RNA.
Given these results and her symptoms at the time of testing, the patient was instructed
to self-isolate and had a telemedicine follow-up appointment in 1 week. At that time,
she reported resolution of her COVID-19 and vulvar symptoms. A follow-up pelvic examination
was then performed 25 days after the vulvar lesion was initially noted. During that
appointment, the vulvar lesion was no longer present, and the patient continued to
report resolution of her COVID-19 and vulvar symptoms.
This patient represents the first reported case of SARS-CoV-2 viral shedding detected
in a vulvar lesion. As nonrespiratory manifestations of COVID-19 are being reported
such as chilblain-like lesions found on fingers and toes of patients with this disease,[3] patients with COVID-19 may have vulvovaginitis as a dermatologic manifestation of
their disease, with unknown viral shedding in these lesions. It is unclear, however,
if this lesion was caused by COVID-19, or rather if viral shedding is occurring in
mucus membrane fissures of any origin and that the origin of the lesion was from another
cause. Whatever the primary etiology, the detectability of SARS RNA in a vulvar lesion
may have implications for health care workers' exposure to SARS-CoV-2 during pelvic
examinations and/or vaginal deliveries. Knowing the virus is detectable in the lower
genital tract, providers may consider the use of certain personal protective equipment
during obstetric or gynecologic examinations. This consideration is of even greater
significance given the presence of asymptomatic disease in patients and close contact
during essential aspects of these physical examinations.[4]
[5]
[6]
Finally, while vertical transmission of COVID-19 to fetuses and newborns has not been
definitively shown,[7]
[8]
[9] the presence of detectable virus in the lower genital tract should prompt continued
studies into this possibility. This may have significance in a variety of obstetric
scenarios (e.g., prolonged rupture of membranes and prolonged second stage of labor).
By highlighting this case, we wish to alert physicians to this phenomenon and these
resulting considerations.
